Drug intelligence / Profile preview

Bufferin Cold

Development stage
Phase 4
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

Bufferin Cold (commonly known as 日夜百服宁 in China) is an over-the-counter combination cold medication developed and manufactured by Sino-American Shanghai Squibb Pharmaceuticals, a joint venture of Bristol Myers Squibb and Shanghai Pharmaceuticals. It is formulated as a day-and-night tablet system designed to relieve symptoms of the common cold and viral upper respiratory tract infections. The daytime formulation (deep orange film-coated tablets) contains acetaminophen (paracetamol) for pain and fever relief, pseudoephedrine hydrochloride as a nasal decongestant, and dextromethorphan hydrobromide as a cough suppressant, without causing drowsiness. The nighttime formulation (deep blue film-coated tablets) includes these three ingredients plus chlorpheniramine maleate, an antihistamine that relieves runny nose and sneezing while promoting restful sleep. Bufferin Cold has been evaluated in clinical trials in China as an active control to assess the efficacy of traditional Chinese medicines, such as Shanggan Granules, in treating acute fever and symptoms of viral upper respiratory tract infections.

Brand names
Bufferin Cold日夜百服宁日夜百服咛
Other names
氨麻美敏片Ⅱ双分伪麻片美扑伪麻片
02

Targets

ADRA1A (α1A)ADRA2A (α2A)ADRB1 (β1)ADRB2 (β2)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1B (α1B)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Bufferin Cold.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bufferin Cold.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call